OVERVIEW
Low-level laser therapy (LLLT), also called photobiomodulation, is being evaluated to treat various conditions including oral mucositis, myofascial pain, joint pain, lymphedema, and chronic wounds.

MEDICAL CRITERIA
Not applicable.

PRIOR AUTHORIZATION
Not applicable.

POLICY STATEMENT
BlueCHiP for Medicare
Low-level laser therapy is covered for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation.

Low-level laser therapy is not covered for all other indications, as the evidence is insufficient to determine the effects of the technology on health outcomes, including but not limited to:

- Carpal tunnel syndrome
- Neck pain
- Subacromial impingement
- Adhesive capsulitis
- Temporomandibular joint pain
- Low back pain
- Osteoarthritic knee pain
- Heel pain (i.e., Achilles tendinopathy, plantar fasciitis)
- Rheumatoid arthritis
- Bell palsy
- Fibromyalgia
- Wound healing
- Lymphedema

Commercial Products
Low-level laser therapy is covered for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation.

Low-level laser therapy is not medically necessary for all other indications, as the evidence is insufficient to determine the effects of the technology on health outcomes, including but not limited to:

- Carpal tunnel syndrome
- Neck pain
• Subacromial impingement
• Adhesive capsulitis
• Temporomandibular joint pain
• Low back pain
• Osteoarthritic knee pain
• Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
• Rheumatoid arthritis
• Bell palsy
• Fibromyalgia
• Wound healing
• Lymphedema

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND
Low-level laser therapy (LLLT) refers to the use of red-beam or near-infrared lasers with a wavelength between 600 and 1000 nm and power between 5 and 500 MW. In contrast, lasers used in surgery typically use 300 Watts. When applied to the skin, LLLT produces no sensation and does not burn the skin. Because of the low absorption by human skin, it is hypothesized that the laser light can penetrate deeply into the tissues where it has a photobiostimulative effect. The exact mechanism of its effect on tissue healing is unknown; hypotheses have included improved cellular repair and stimulation of the immune, lymphatic, and vascular systems. LLLT is being evaluated to treat a wide variety of conditions, including soft tissue injuries, myofascial pain, tendinopathies, nerve injuries, and joint pain. LLLT has also been evaluated for lymphedema.

ORAL MUCOSITIS
Oral mucositis describes inflammation of the oral mucosa and typically manifests as erythema or ulcerations that appear 7 to 10 days after initiation of high-dose cancer therapy. Oral mucositis can cause significant pain and increased risk of systemic infection, dependency on total parenteral nutrition, and use of narcotic analgesics.

Treatment
Treatment planning may also need to be modified due to dose-limiting toxicity. There are a number of interventions for oral mucositis that may partially control symptoms, but none is considered a criterion standard treatment. When uncomplicated by infection, oral mucositis is self-limited and usually heals within 2 to 4 weeks after cessation of cytotoxic chemotherapy. Low-level laser therapy (LLLT) has been used to treat cancer therapy–induced oral mucositis in patients treated with radiotherapy and/or chemotherapy and hematopoietic cell transplantation.

MUSCULOSKELETAL AND NEUROLOGIC DISORDERS
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and the most commonly performed surgery of the hand. The syndrome is related to the bony anatomy of the wrist. The carpal tunnel is bound dorsally and laterally by the carpal bones and ventrally by the transverse carpal ligament. Through this contained space run the 9 flexor tendons and the median nerve. Therefore, any space-occupying lesion can compress the median nerve and produce the typical symptoms of CTS - pain, numbness, and tingling in the distribution of the median nerve. Symptoms of more severe cases include hypesthesia, clumsiness, loss of dexterity, and weakness of pinch. In the most severe cases, patients experience marked sensory loss and significant functional impairment with thenar atrophy.

Treatment
Mild-to-moderate cases of CTS are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs, and steroid injections into the carpal tunnel itself. Patients who do not respond to conservative therapy or who present with severe CTS with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach. LLLT is also used to treat CTS.

For individuals who have increased risk of oral mucositis due to some cancer treatments (eg, chemotherapy, radiotherapy) and/or hematopoietic cell transplantation who receive LLLT, the evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

The evidence for LLLT is insufficient to determine the effects of the technology on health outcomes in individuals who have the following conditions:

- orthopedic pain (ie, neck pain, osteoarthritic knee pain, low back pain, carpal tunnel syndrome)
- shoulder conditions (eg, subacromial impingement syndrome, adhesive capsulitis), heel pain, or temporomandibular joint pain
- bone, ligament, and joint conditions (eg, rheumatoid arthritis, fibromyalgia)
- Bell palsy
- lymphedema
- chronic non-healing wounds

**CODING**

**BlueCHiP for Medicare and Commercial Products**

Providers should file the following HCPCS code, as there isn't a specific CPT code for the service. The following code is covered when filed with the ICD-10 diagnosis codes below.

**S8948** Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes

ICD-10 CM: C00 - D49

**RELATED POLICIES**

Not applicable

**PUBLISHED**

Provider Update, January 2020
Provider Update, September 2018
Provider Update, January 2018
Provider Update, January 2017
Provider Update, February 2016

**REFERENCES**

12. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Low-level laser therapy for carpal tunnel syndrome and chronic neck pain. TEC Assessment Nov 2010;Volume 25:Tab 4. PMID 21638940